A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04708418 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Recurrent Cutaneous Melanoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography
PROCEDURE: Surgical Procedure
DRUG: VLP-encapsulated TLR9 Agonist CMP-001

Sponsor

National Cancer Institute (NCI)